Indonesian supervolcano’s eruption caused decade of fatal winters 74,000 years ago

Washington, July 4 (ANI): Climate model simulations by a team of scientists has suggested that Indonesia’s Toba supervolcano, when it erupted about 74,000 years ago, triggered a 1,000-year episode of ice sheet advance, and also may have produced a short-lived “volcanic winter”, which drastically reduced the human population at the time.

Previous climate model simulations of the eruption have been unable to produce the glaciation, and there are no climate observations to support the volcanic winter.

To investigate additional mechanisms that may have enhanced and extended the effects of the Toba eruption, as well as the volcanic winter, Alan Robock and his team from Rutgers University, US, have conducted six climate model simulations using state-of-the-art models that include vegetation death effects on radiation budgets, and stratospheric chemistry feedbacks that might affect the lifetime of the volcanic cloud.

The researchers used a wide variety of aerosol injection volumes, ranging from 33 to 900 times that of the 1991 Mount Pinatubo injection.

They found that none of the models initiate glaciation.

Nonetheless, they produce a decade of severe volcanic winter, which would likely have had devastating consequences for humanity and global ecosystems, supporting the idea that the Toba eruption produced a genetic bottleneck in human evolution. (ANI)

Bill and Melinda Gates pour thousands into unconventional health research

London, May 5 (ANI): Bill and Melinda Gates Foundation has thrown a lifeline to number of projects like creating an anti-viral tomato, a flu-resistant chicken and a magnet that can detect malaria, awarding 81 grants of one lakh dollar each in a bid to support innovative, unconventional global health research.

The five-year health research grants are designed to encourage scientists to pursue bold ideas that could lead to breakthroughs, focusing on ways to prevent and treat infectious diseases, such as HIV, malaria, tuberculosis, pneumonia and diarrhoeal diseases.
Among the grant recipients is Eric Lam at Rutgers University in New Jersey, who is exploring tomatoes as an antiviral drug delivery system, The Telegraph reported.

Three British scientific teams, pursuing novel approaches to preventing and treating infectious diseases such as tuberculosis, malaria and pneumonia, have been chosen.

One team, led by researchers at the University of Exeter in Devon, England, will seek to build an inexpensive instrument to diagnose malaria by using magnets to detect the waste products of the malaria parasite in human blood.

Scientists from Royal Holloway University, London, are attempting to compile a library of all possible mutations of HIV with the ultimate goal of a vaccine that can protect against many variant forms of the virus.

Each grant recipient will also get the chance of follow-on grants of one million dollar if their projects show success.

Applicants were selected from more than 3,000 proposals, with all levels of scientists represented – from veteran researchers to postgraduates – and a range of disciplines, such as neurobiology, immunology and polymer science. (ANI)

Altered gene may make some people prone to schizophrenia

Washington, April 8 (ANI): Rutgers geneticists have announced the discovery of a specific DNA change that may make some people prone to schizophrenia.

Lead researcher Linda Brzustowicz says that her team’s study provides a potential mechanism that may be a point of entry for drug therapy, consistent with the growing trend of personalized medicine.

She said that the study revealed a functional DNA change that increases gene expression.

She and her colleagues made this finding while studying a Canadian population of 24 families where multiple individuals had been diagnosed with schizophrenia.

The researchers revealed that the gene in question is NOS1AP, previously known as CAPON.

Linda, however, added that schizophrenia is not a single-gene disorder, and that there are environmental factors that are also important.

“It is not as though, if you have this altered gene, you will get the disease,” she said.

A research article on this study has been published in the American Journal of Psychiatry (AJP). (ANI)

Earliest humans walked on anatomically modern feet 1.5 million years ago

Washington, Feb 27 (ANI): Scientists have found ancient footprints in Kenya that show some of the earliest humans walked like us and did so on anatomically modern feet 1.5 million years ago.

This anatomical interpretation is the conclusion of Rutgers Professor John W.K. Harris and an international team of colleagues.

From 2006 to 2008, the field school group of mostly American undergraduates, including Rutgers students, excavated the site yielding the footprints.

The footprints were discovered in two 1.5 million-year-old sedimentary layers near Ileret in northern Kenya.

These rarest of impressions yielded information about soft tissue form and structure not normally accessible in fossilized bones.

The Ileret footprints constitute the oldest evidence of an essentially modern human-like foot anatomy.

To ensure that comparisons made with modern human and other fossil hominid footprints were objective, the Ileret footprints were scanned and digitized by the lead author, Professor Matthew Bennett of Bournemouth University in the UK.

The upper sediment layer contained three footprint trails: two trails of two prints each, one of seven prints and a number of isolated prints.

Five meters deeper, the other sediment surface preserved one trail of two prints and a single isolated smaller print, probably from a juvenile.

In these specimens, the big toe is parallel to the other toes, unlike that of apes where it is separated in a grasping configuration useful in the trees.

The footprints show a pronounced human-like arch and short toes, typically associated with an upright bipedal stance.

The size, spacing and depth of the impressions were the basis of estimates of weight, stride and gait, all found to be within the range of modern humans.

Based on size of the footprints and their modern anatomical characteristics, the researchers attribute the prints to the hominid Homo ergaster, or early Homo erectus as it is more generally known.

This was the first hominid to have had the same body proportions (longer legs and shorter arms) as modern Homo sapiens. (ANI)

Why men like wet kisses with more ‘tongue action’

Washington, Feb 18 (ANI): When you share a kiss with your man, you reveal a lot more than just passion. US scientists have found that modern man uses smooch to pick up traces of estrogen in a woman’s saliva and thus gauge her fertility.

Anthropologist Helen Fisher of Rutgers University says that such behaviour may explain why men like wet kisses with more “tongue action”.

While at a meeting of the American Association for the Advancement of Science in Chicago, Fisher said that wet kisses could also be an unconscious attempt to transfer testosterone to the woman, which would stimulate her sexual interest.

“Men see kissing early in a relationship directly as a step to copulation,” she said.

According to Wendy Hill, a neuroscientist at Lafayette College in Easton, Pennsylvania, kissing may also serve as a way to assess the quality of a mate.

Fisher said that research has shown that the majority of men and women rate their first kiss as either “the kiss of death” or the blossoming of a new relationship.

The expert recently developed a personality test that measures four universal temperaments by using statistics from 40,000 people on the Internet dating site Chemistry.com.

Each temperament type was linked to activity levels of the brain chemicals dopamine/norepinephrine, serotonin, testosterone, and estrogen/oxytocin.

Fisher found that a person’s temperament guides which type of mate they select-boosting her belief that love involves some very powerful brain chemistry.

“People sing for love; they dance for love; they write about love; live for, kill, and die for love,” Fisher told National Geographic News.

“It’s a wonderful addiction when [a relationship is] working well-but perfectly horrible when it’s working poorly,” she added. (ANI)

New gene-silencing platform that can lead to treatments for diseases resistant to current RNAi methods

London, February 16 (ANI): Rutgers University researchers in New Jersey, US, say that they have created a gene-silencing platform, which may enable the development and discovery of a new class of drugs to treat a wide array of diseases.

The researchers have revealed that critical to the technology is the approach they specifically took to target RNA biosynthesis.

Research leader Samuel Gunderson, an associate professor in the Department of Molecular Biology and Biochemistry at Rutgers, claims that his team have developed highly efficient gene silencing agents that function via a novel mechanism of action.

According to him, the agents are single-stranded oligonucleotides, called U1 Adaptors, which have dual and independent functions.

The researcher says that first is a target-gene binding domain that can be tailored to any gene, while the second domain inhibits mRNA maturation by binding U1 snRNP, a component of the cellular splicing apparatus.

Gunderson suggests that combining both capabilities in the same molecule can enable the U1 Adaptor to inhibit the pre-mRNA maturation step of polyA tail addition in a gene specific manner.

Further, the domains of the oligonucleotide are independent so transcript binding and U1 snRNP binding can be independently optimized and adapted to a wide array of genes associated with disease.

“The U1 Adaptor platform expands on early technologies that used 5′-end-mutated U1 snRNA. The U1 Adaptor is an oligonucleotide version of this older method and instead targets the 3′ end processing step. U1 Adaptors have high activity when used alone and are synergistic when used in combination with RNAi,” Nature magazine quoted Gunderson as saying.

The researcher further said that the range of possible targets was very broad due to the mechanism of action in which inhibition occurs during the biosynthesis of mRNA at the near universal 3′ end processing step.

He even suggests that U1 Adaptors can possibly inhibit genes that do not respond to current RNAi methods.

A research paper on this project has been published in the journal Nature Biotechnology. (ANI)

New gene silencing platform developed to cure RNAi-resistant diseases

London, Feb 9 (ANI): Taking a step beyond RNA interference (RNAi), scientists have now developed a novel gene silencing platform that may enable the development and discovery of a new class of drugs to treat a wide array of diseases resistant to current RNAi.

Led by Rutgers’ Samuel Gunderson, the researchers developed the technology with an approach to specifically target RNA biosynthesis.

The platform boasts very significant improvements over existing RNAi approaches.
RNA interference (RNAi) is a system within living cells that helps control which genes are active and how active they are.

The highly efficient gene silencing agents use a novel mechanism of action for their functioning.

The agents are single-stranded oligonucleotides, called U1 Adaptors, that have dual, and independent, functions. First is a target-gene binding domain that can be tailored to any gene. The second domain inhibits mRNA maturation by binding U1 snRNP, a component of the cellular splicing apparatus.

By combining both capabilities in the same molecule, the U1 Adaptor can inhibit the pre-mRNA maturation step of polyA tail addition in a gene specific manner.

Also, the domains of the oligonucleotide are independent, thus transcript binding and U1 snRNP binding can be independently optimised and adapted to a wide array of genes associated with disease.

“The U1 Adaptor platform expands on early technologies that used 5′-end-mutated U1 snRNA,” Nature magazine quoted Gunderson an associate professor in the Department of Molecular Biology and Biochemistry at Rutgers, The State University of New Jersey, as saying.

He added: “The U1 Adaptor is an oligonucleotide version of this older method and instead targets the 3′ end processing step. U1 Adaptors have high activity when used alone and are synergistic when used in combination with RNAi.”

He also said that the range of possible targets was very broad due to the mechanism of action in which inhibition occurs during the biosynthesis of mRNA at the near universal 3′ end processing step.

In his opinion, the most interesting aspect of this technology is that U1 Adaptors can possibly inhibit genes that do not respond to current RNAi methods.

The applications of U1 Adaptors expand on those currently available using standard RNAi approaches. They can be used as a research tool to determine gene function and to validate gene targets.

Gene silencing molecules also have potential prophylactic and therapeutic applications based upon ongoing clinical trials using RNAi and traditional antisense approaches.

The research findings have been reported in the online edition of Nature Biotechnology. (ANI)